N-carbobenzyloxy-D-leucine isopentylamide | 148528-70-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-carbobenzyloxy-D-leucine isopentylamide
• 英文别名: benzyl N-[(2R)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamate
• CAS: 148528-70-5
• 化学式: C₁₉H₃₀N₂O₃
• 分子量: 334.459
• InChiKey: OJJZSCBUIKSSQM-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-carbobenzyloxy-D-leucine isopentylamide 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 N1-异戊烷-D-亮氨酰胺
  参考文献：
  名称：

  N-Haloacetyl-amino-acid amides as active-site-directed inhibitors of papain and cathepsin B

  摘要：

  A series of N-haloacetyl-amino-acid amides were synthesized and tested as models of cysteine-protease inhibitors. They irreversibly inactivated papain and cathepsin B via a reversible enzyme--inhibitor intermediate. Apparent second-order rate constants of inactivation ranging from 65 to 16 700 M-1 s-1 were observed. Reactivity against papain, as compared to glutathione, was increased 16 400-fold for N-bromoacetyl-leucine isopentylamide and 25 700-fold for the corresponding iodoacetyl derivative; these increases are probably due to proximity effects. No inhibition of trypsin, chymotrypsin and porcine pancreatic elastase was observed. Haloacetamides represent an interesting class of easily synthesized, efficient. irreversible inhibitors of cysteine proteases, which have low non-specific alkylating properties.

  DOI：

  10.1016/0223-5234(92)90018-v
• 作为产物：
  描述：

  N-苄氧羰基-D-亮胺酸 在 N-甲基吗啉 作用下， 以 二氯甲烷 为溶剂， 反应 15.5h， 生成 N-carbobenzyloxy-D-leucine isopentylamide
  参考文献：
  名称：

  N-Haloacetyl-amino-acid amides as active-site-directed inhibitors of papain and cathepsin B

  摘要：

  A series of N-haloacetyl-amino-acid amides were synthesized and tested as models of cysteine-protease inhibitors. They irreversibly inactivated papain and cathepsin B via a reversible enzyme--inhibitor intermediate. Apparent second-order rate constants of inactivation ranging from 65 to 16 700 M-1 s-1 were observed. Reactivity against papain, as compared to glutathione, was increased 16 400-fold for N-bromoacetyl-leucine isopentylamide and 25 700-fold for the corresponding iodoacetyl derivative; these increases are probably due to proximity effects. No inhibition of trypsin, chymotrypsin and porcine pancreatic elastase was observed. Haloacetamides represent an interesting class of easily synthesized, efficient. irreversible inhibitors of cysteine proteases, which have low non-specific alkylating properties.

  DOI：

  10.1016/0223-5234(92)90018-v

文献信息

• Novel Drugs for Dementia
  申请人：Ternansky Robert

  公开号：US20080227806A1

  公开（公告）日：2008-09-18

  The invention is directed to compounds that are prodrugs containing a chemical delivery system (CDS) moiety and a cysteine protease inhibitor moiety. The CDS moiety targets the prodrug to the brain or central nervous system. The cysteine protease inhibitor inhibits cysteine proteases upon release from the prodrug. Cysteine protease inhibitors are effective for treating dementia, Alzheimer's disease and vascular dementia. Targeting the brain or central nervous system offers significant advantages in treating these conditions and diseases. A preferred CDS prodrug is a dihydrotrigoneline CDS moiety coupled to an epoxysuccinyl peptide cysteine protease inhibitor moiety.

  本发明涉及一种含有化学递送系统（CDS）基团和半胱氨酸蛋白酶抑制剂基团的前药化合物。CDS基团将前药定位于大脑或中枢神经系统。半胱氨酸蛋白酶抑制剂在从前药中释放后抑制半胱氨酸蛋白酶。半胱氨酸蛋白酶抑制剂对治疗痴呆症、阿尔茨海默病和血管性痴呆症有效。定位于大脑或中枢神经系统在治疗这些疾病和症状方面具有显著的优势。首选的CDS前药是将二氢三角线CDS基团与环氧丙酰肽半胱氨酸蛋白酶抑制剂基团耦合。
• WO2007/38772
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] NOVEL DRUGS FOR DEMENTIA<br/>[FR] NOUVEAUX MEDICAMENTS CONTRE LA DEMENCE
  申请人：TERNANSKY ROBERT

  公开号：WO2007038772A1

  公开（公告）日：2007-04-05

  [EN] The invention is directed to compounds that are prodrugs containing a chemical delivery system (CDS) moiety and a cysteine protease inhibitor moiety. The CDS moiety targets the prodrug to the brain or central nervous system. The cysteine protease inhibitor inhibits cysteine proteases upon release from the prodrug. Cysteine protease inhibitors are effective for treating dementia, Alzheimer's disease and vascular dementia. Targeting the brain or central nervous system offers significant advantages in treating these conditions and diseases. A preferred CDS prodrug is a dihydrotrigoneline CDS moiety coupled to an epoxysuccinyl peptide cysteine protease inhibitor moiety.
  [FR] L'invention concerne des composés qui sont des promédicaments contenant un fragment de système de délivrance chimique ("chemical delivery system" ou CDS) et un fragment d'inhibiteur de cystéine protéase. Le fragment CDS cible le promédicament sur le cerveau ou le système nerveux central. L'inhibiteur de cystéine protéase inhibe les cystéine protéases lors de la libération du promédicament. Les inhibiteurs de cystéine protéase sont efficaces dans le traitement de la démence, de la maladie d'Alhzheimer et de la démence vasculaire. Le ciblage du cerveau ou du système nerveux central offre des avantages significatifs dans le traitement de ces états et maladies. Un médicament CDS préféré est composé d'un fragment CDS de dihydrotrigoneline couplé à un fragment d'inhibiteur de cystéine protéase de peptide d'époxysuccinile.
• N-Haloacetyl-amino-acid amides as active-site-directed inhibitors of papain and cathepsin B
  作者：C Giordano、C Gallina、V Ottaviano、V Consalvi、R Scandurra

  DOI：10.1016/0223-5234(92)90018-v

  日期：1992.12

  A series of N-haloacetyl-amino-acid amides were synthesized and tested as models of cysteine-protease inhibitors. They irreversibly inactivated papain and cathepsin B via a reversible enzyme--inhibitor intermediate. Apparent second-order rate constants of inactivation ranging from 65 to 16 700 M-1 s-1 were observed. Reactivity against papain, as compared to glutathione, was increased 16 400-fold for N-bromoacetyl-leucine isopentylamide and 25 700-fold for the corresponding iodoacetyl derivative; these increases are probably due to proximity effects. No inhibition of trypsin, chymotrypsin and porcine pancreatic elastase was observed. Haloacetamides represent an interesting class of easily synthesized, efficient. irreversible inhibitors of cysteine proteases, which have low non-specific alkylating properties.